The APP gene test looks for disease-causing changes in the APP gene, usually ordered with PSEN1 and PSEN2, that can cause inherited early-onset Alzheimer's disease. For a younger adult with memory problems, coverage often depends on family history and referral details, and cost depends on CPT codes, prior authorization, and self-pay options.
APP makes amyloid precursor protein, and certain variants disrupt normal processing. Testing is not routine memory care. It fits a narrow situation: early symptoms plus a pattern that suggests autosomal-dominant family risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is this test for?
- Will insurance cover it?
- What could it cost without coverage?
- What should you ask before referral?
- What legal limits should families know?
- Frequently Asked Questions
Who is this test for?
Early-onset means symptoms start before age 65. It represents about 5% of Alzheimer's cases, according to Evexia Diagnostics, in its early-onset Alzheimer's NGS diagnostic test page. The National Institute on Aging says a neurologist or other specialist may order APP plus PSEN1/PSEN2 testing when a younger adult has early-age symptoms and a strong family history, as described in its Alzheimer's disease genetics fact sheet. APOE testing is different.
It cannot fully predict disease and is mainly for research. A child of a carrier has a 50% chance of inheriting the variant. Lifetime risk is very high, often with onset in the 30s to mid-60s. Among familial cases, PSEN1 accounts for the largest share, followed by APP and then PSEN2.
Will insurance cover it?
Blue Cross NC describes APP/PSEN1/PSEN2 testing as medically necessary when results will inform reproductive decision-making. Eligible cases include autosomal-dominant family history, a first-degree relative with a known mutation, or suspected early-onset disease with unknown history such as adoption. The same policy calls testing investigational and not covered to confirm Alzheimer's diagnosis alone.
It also excludes risk assessment, screening without symptoms, testing children under 18, and other genes including APOE outside drug-label guidance. Readers with other plans should not assume the same rules. Ask whether your plan follows a similar policy. Get the answer in writing before blood is drawn.
What could it cost without coverage?
The billed amount depends on how the lab codes the test. Examples listed for early-onset panels include CPT codes 81405, 81406, and 81479. Those codes affect prior authorization and patient share. Ask the ordering clinic for the exact codes, the lab name, and whether authorization is required.
Also ask for the self-pay price in advance. Invitae has advertised $475 per-indication self-pay and sponsored neurodegenerative-disease testing. Availability changes by program. Ask whether any sponsored option is open now.
What should you ask before referral?
Australian GP guidance says testing may fit when two or more relatives were affected before 65. It recommends referral to genetics services rather than testing alone, with formal counseling and a Huntington-disease-style disclosure protocol, according to the Royal Australian College of General Practitioners in its Alzheimer disease genomics guidance. That referral matters because results affect relatives, family planning, and future care.
Counseling covers consent, possible outcomes, and who receives results. It can also clarify whether an affected relative should be tested first. Bring these questions to the visit:.
- Should I see genetics before neurology, or both together?
- Should an affected parent or sibling be tested first?
- What pre- and post-test counseling is included?
- Which CPT codes will be billed, and is prior authorization needed?
- What are the self-pay and sponsored-testing options?
What legal limits should families know?
U.S. federal law GINA prohibits health insurers and employers from discriminating based on genetic information. That protection includes test results and family-history data.
GINA does not cover every insurance type. Patients should still ask counselors about life, disability, and long-term-care insurance. Also ask what employment documentation the clinic will keep and who can see it.
Frequently Asked Questions
Can this test diagnose my memory problems?
No. Insurers may deny it when used only to confirm Alzheimer's. Its main use is assessing inherited early-onset risk when symptoms and family history point that way.
Should I get tested without symptoms because my parent had Alzheimer's after 70?
Usually no. Late-onset family history alone does not meet familial early-onset criteria. Ask your doctor whether genetics referral is warranted.
Why might the doctor suggest testing my affected relative first?
A positive result in an affected person clarifies which variant runs in the family. That makes your own result easier to interpret.
